STX - Proactive Research Analyst says Shield Therapeutics' commercialisation drive going well
(NewsDirect)
ProactiveResearch Analyst Robin Davison speaks to Thomas Warner afterpublishing a new research note on Shield Therapeutics PLC, followingthe release of new prescription data from the commercial-stagespecialty pharmaceutical company for its iron deficiency treatmentAccrufer/Feraccru. The key highlight from the analysis is thesignificant increase of 50% in prescriptions during the secondquarter, specifically for Accrufer. The number of doctors prescribingthe drug for the first time has also shown a positive trend, with aconsiderable proportion of those doctors continuing to prescribe it inthe following quarter. Davison says that the company's efforts incommercialising the product are "going well", with morebenefit expected to come following the expansion of their sales forcein June.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.